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A method is described for the detection of certain nucleotide modifications adjacent to the 5’ 7-methyl
guanosine cap of mRNAs from individual genes. The method quantitatively measures the relative
abundance of 2’-O-methyl and N6,2’-O-dimethyladenosine, two of the most common modifications. In
order to identify and quantitatify the amounts of N6,2’-O-dimethyladenosine, a novel method for the
synthesis of modified adenosine phosphoramidites was developed. This method is a one step synthesis and
the product can directly be used for the production of N6,2’-O-dimethyladenosine containing RNA
oligonucleotides. The nature of the cap-adjacent nucleotides were shown to be characteristic for mRNAs
from individual genes transcribed in liver and testis.
I
n most eukaryotes, polymerase II (Pol II) dependent transcripts are modified co-transcriptionally at their
5’end by the addition of a 7-methyl guanosine (m7G) cap to the first nucleoside of the nascent transcript. If no
additional modifications are made to the cap-adjacent nucleotides, the structure is referred to as a cap0. In
yeast and plants, only cap0 structures are found, however, in animals, modifications of the two nucleotides
adjacent to the m7G are possible The methylation of the first nucleotide on the ribose residue (Fig. 1a) will form
a cap1 structure1. Cap1 messages can be converted to cap2 structures if a further 2’ribose methylation takes place
on the next nucleotide following the cap1 (Fig. 1b). These methylation steps are sequential and carried out by
nuclear located methylases1–3. In a transcript where the first nucleotide is an adenosine in a cap1 structure, a
further methylation of the 2’-O-dimethyladenosine (Am) at the N6 position of the adenine can take place to give
N6,2’-O-dimethyladenosine (m6Am) (Fig. 1c)4. The methyltransferase that carries out this modification has been
partially characterized and appears to be predominantly located in the cytoplasm5. Transcription start sites of
focused promoters are usually contained within an initiator motif (Inr) of general sequence YYANWYY
(Y5pyrimidine, N-any nucleotide, W5A or T) where the A is the principal start site and neighbouring nucleo-
tides may be used to varying degrees6. Since, A is often the first nucleotide after the m7G cap, its modification may
have a functional role. In order to study the effect of m6Am present in cap1 messages, the chemical synthesis of
RNA oligonucleotide sequences that containm6Am in well-defined positions, is necessary. A number of methods
exist in the literature for the preparation of N6-methylated adenosine derivatives, with the Dimroth rearrange-
ment being perhaps the most well known7–9. This transformation relies upon an initial N1-methylation of the
adenine ring followed by an alkali-mediated rearrangement to give the N6-methylated adenine product. An
alternative method for accessing N6-alkylated adenines has been developed, which involves the nucleophilic
aromatic substitution of adenine derivitives, that are activated at the 6-position, with amine nucleophiles (i.e.
MeNH2)10–13. In order to obtain the N6-methylated phosphoramidite reagents from these adenine derivatives, a
number of additional synthetic steps are required, which results in a 6 to 8 step synthesis being needed to produce
each phosphoramidite reagent10–13. Such approaches are not realistic other than in synthetic chemistry laboratories.
An interaction of m7G capped transcripts with the nuclear cap-binding complex (CBC) is important for
promoting correct splicing14 and 3’end formation15. After export from the nucleus, translation of most
mRNAs is initiated with the recognition of the m7G cap by eukaryotic translation initiation factor 4E
(eIF4E)16. This cap binding step is usually rate-limiting for translation. The m7G cap also protects the message
from 5’ to 3’ exonuclease digestion. Compared to the well characterised role of m7G, relatively little is known
regarding the function of 2’ ribosemethylation on the following nucleotides. The presence of a cap1 structuremay
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promote binding to ribosomes17 and can increase translational effi-
ciency in vitro18, 19. Many animal viruses encode their own cap1
methylases20, 21 and this may also help them to limit host immune
responses22, 23. Whilst viral cap1 methylases are common viral cap2
methylases and m6Ammethylases have not been reported. However,
m6Am and cap2 structures can be found in viral mRNAs in vivo,
presumably as a result of the action of the host cell’s enzymes24. The
functional consequences for anmRNAof possessingm6Am in a cap1
or a cap2 structure are not known.
In order to investigate the roles of these cap-associated modifica-
tions, we have developed enzymatic techniques, in combination with
thin layer chromatography (TLC) that allow the detection of m6Am
and other cap nucleotides. We also describe a direct synthetic
method for the preparation of the desired m6Am phosphoramidite
reagent in a single step from commercially available startingmaterial.
Through the use of this synthetic substrate we have demonstrated
that a thin layer chromatography (TLC) method is quantitative for
determining m6Am:Am ratios, and allows the relative proportions of
Am and m6Am to be rapidly determined for mRNAs from different
cell types and also for caps of messages from individual genes. We
further give evidence that the relative proportion of m6Am varies in a
characteristic way for mRNA from different mouse organs.
Results
Synthesis and detection of N6, 2’-O- dimethyladenosine. We have
previously used TLC assays to detect and quantify N6-methyladeno-
sine (m6A)25, a modification found internally in the mRNA of many
eukaryotes26–29. This method was modified to label and detect only
the first nucleotide after the cap. In order to use this approach to
compare the relative proportions of m6Am and Am in cap structures
from different sources, it was first necessary to establish the mobility
of m6Am in the TLC assay and to demonstrate that T4 polynucleo-
tide kinase does not preferentially label either of these nucleotides. As
neitherm6Am triphosphate orm6Amphosphoramidite are commer-
cially available, a novel method for its synthesis and incorporation
into RNA oligonucleotides was developed.
In order to get quick access to the required m6Am phosphorami-
dite building block for solid-phase oligoribonucleotide synthesis, we
performed a selective one-step methylation of the commercially
available 2’-OMe-Bz-A-CE phosphoramidite. Due to its high reac-
tivity and sensitivity towards acids and bases, Aritomo’s relatively
mild phase transfer catalysis (PTC) method was used30. Under these
conditions (iodomethane, sodium hydroxide, tetrabutylammonium
bromide) the N6-methylated product was obtained as the major
product in 56% yield, with the N1-methylated isomer being
formed as a byproduct in 25% yield. Due to their different Rf values,
the N6- and N1-methylated products were easily separated via
column chromatography, and the purified m6Am phosphoramidite
was used directly for RNA synthesis.
All oligoribonucleotides were synthesized using the standard pro-
tocol for solid-phase RNA synthesis with a 15 min coupling time per
nucleotide. The last coupling step was followed by a standard DMTr-
off procedure, the oligoribonucleotides were removed from the solid
support, deprotected, precipitated and desalted. MALDI mass spec-
trometry was used to confirm the mass of all RNA oligonucleotides
produced
Thin layer chromatography of modified adenosines. Radioactively
5’ end labelled oligonucleotides SK-526 (m6AmGGGCUGCU) and
SK-524 (AmGGGCUGCU) were digested to release pm6Am and
pAm then mixed with a combination of 5’ radioactive labelled
pm6A and unmodified nucleotide monophosphates for which rela-
tive mobilities are well characterised. This mixture was separated by
2D TLC using the solvent systems previously described25 to establish
the position of pm6Am (Fig. 2).
To show that T4 polynucleotide kinase does not preferentially
label m6Am or Am, the RNA oligonucleotides SK-524 and SK-526
weremixed in different ratios, end labelled, digested with P1 nuclease
and separated by TLC. The spots corresponding to pm6Am and pAm
were then quantified using phosphorimaging. The results demon-
strated that both nucleotides are labelled with equal efficiency by T4
polynucleotide kinase (Fig. 3)
Labelling and analysis of the first cap adjecent nucleotide. To label
the first nucleotide following the m7G, poly(A) RNA was prepared
from various mouse organs then digested with tobacco acid pyro-
phosphatase to remove the m7G cap. The exposed 5’ ends were
dephosphorylated with alkaline phosphatase and after phenol/chlo-
roform extraction and ethanol precipitation, the mRNA transcripts
were radiolabelled at their 5’ end using T4 polynucleotide kinase in
the presence of .20 fold excess of [c-32P] ATP. The labelled RNA
was digested to monophospho-nucleotides by P1 nuclease prior to
TLC separation. Using this method, new spots corresponding to the
2’-O methylated nucleotides are apparent in the labelled samples
after cap removal (Fig 4A). A spot corresponding to pm6Am is read-
ily detectable in all mRNA samples tested, and with pm6Am:pAm
ratios of between 15:1 (brain) and 2:1 (liver) it appears that m6Am is
more prevalent at the cap1 than is Am (Fig. 4A). Under these label-
ling conditions, where both ATP and polynucleotide kinase are in
excess, the intensity of the spots corresponding to the unmodified
Figure 1 | Cap adjacent modification in higher Eukaryotes. Formation of
the cap1 structure takes place by 2’-O –methylation on the ribose residue
on the first nucleotide adjacent to the m7G cap. The example shows a
structure with adenosine as the first nucleotide, adjacent to the m7G cap
(a). The cap1 structure can then be converted to a cap2 by a further 2’-O-
ribose methylation on the following nucleotide (b), or converted to a cap1
m6Am by placing a further methyl group on the adenosine in the N6
position (c). The figure is a schematic representation of the mRNA cap
structures. The yellow structure represents 7-methyl-guanine, the green
represents adenine and the grey pentagon is ribose. On the ribose only the
methylated functional groups are shown.
www.nature.com/scientificreports
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nucleotides, as well as the other 2’ methylated nucleotides, is indi-
cative of their actual relative abundance in the de-capped mRNA
sample (Supplementary Figure S1 online).
Analysis of cap structures for mRNA transcripts from individual
genes. In order to assay modifications on the first transcribed
nucleotide for messages from individual genes, mRNA from liver
and testis was de-capped and end-labelled as described above then
fragmented to,120 nt. This was then hybridised to single stranded
DNA targets corresponding to the 5’ region of selected messages.
These DNA targets were first cross-linked to 2 mm 3 2 mm teeth
cut from a Hybond N1membrane. After hybridization and washing,
the membrane was subjected to phosphorimaging (Fig. 4B). The
individual teeth containing the labelled mRNA gene-specific frag-
ments were then removed and digested to nucleotide 5’ monopho-
sphates using P1 nuclease. These samples were individually spotted
onto TLC plates and developed as described (Fig. 4B). Four mRNAs
were chosen for analysis, apolipoprotein A-I (Apoa1, BC012253),
albumin (Alb, BC024643), protamine 2 (Prm2, BC049612) and
poly(A) binding protein cytoplasmic 1 (Pabpc1, BC046233). Alb
and Apoa1 are predominantly liver expressed messages, whereas
Prm2 shows testis specific expression and Pabpc1 is expressed highly
in both organs. Pabpc1may be subjected to translational regulation,
but unlike Pabpc2, it is present in actively translating polyribosomes
of mouse testicular cells31. For both Alb and Apoa1, the labelled
nucleotide in the cap adjacent position included A, G, U and C, as
well as m6Am and Am. This is consistent with multiple alternative
transcription start sites at and around the Inr32. In both cases, Am
and m6Am appeared as the major nucleotide modifications; unlike
the mixed mRNA starting material, 2’-O-methylcytosine was not
present (compare Fig. 4A, B). The m6Am:Am ratios were 1.65:1
and 1.4:1 for Apoa1 and Alb respectively, which is only slightly lower
compared to that seen for the livermRNApopulation as a whole. The
Prm2mRNAs from testis tissues almost exclusively had m6Am at the
cap adjacent position (Fig. 4B). With an m6Am:Am ratio of 40:1, this
was four times larger than the m6Am:Am ratio for the testis mRNA
population as a whole. In contrast the cap adjacent nucleotides of
Pabpc1 transcripts were predominantly unmodified, although a pro-
nounced 2’-O-methyluridine was apparent in the sample from testis
(Fig. 4B).
Discussion
Core promoters of Pol II transcribed genes may be focused, directing
transcription initiation at a single site or cluster of adjacent sites, or
they may be dispersed and have multiple start sites over a region of
50–100 nucleotides6. In case of focused promoters the transcription
Figure 2 | Relative mobility of modified adenosines using 2 dimensional thin layer chromatography. RNA oligonucleotide fragments of known
compositions were labelled at their 5’ ends with32P, digested to 5’monophosphates and separated by 2 dimensional thin layer chromatography in order to
establish the mobility of pm6Am relative to other nucleotides. Adenosine and its methylated derivatives are indicated by shading.
Figure 3 | T4 polynucleotide kinase does not preferentially labelm6Amor
Am containing ends. The oligonucleotides SK-526 (m6Am) and SK-524
(Am)weremixed in ratios of 5:1, 2:1, 1:1. 1:2 and 1:5, end labelled using T4
polynucleotide kinase, digested to 5’ phosphate mononucleotides and
separated by TLC. The relative intensities of the resulting spots were
quantified using phosphorimaging. The calculated percentage of m6Am
closely matched the actual m6Am percentage.
www.nature.com/scientificreports
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start sites are contained within and around the Inr (YYANWYY),
where theA is the principal start site and surrounding nucleotides are
utilised to varying degrees6. Recent high-throughput sequencing
from full length mRNAs, suggests that purine instead of A may be
a better representation of the Inr consensus. However, most core
promoters have several closely arrayed transcription start sites with
different initiation rates rather than initiating at a single nucleotide32.
Thus, most genes will give rise to a population of mRNAs that differ
in their starting nucleotides. For example the Prm2message initiates
predominantly at the central A of the Inr as well as a second A 3
Figure 4 | Relative abundance of modified adenosines in mRNA from different mouse organs and in individual mRNAs. (A) 2’-O-methylated
nucleotides are present in the mRNA populations from various mouse organs. Arrow indicates m6Am. Different organs have characteristic m6Am:Am
ratios; brain (15:1), kidney (2.4:1), liver (2:1), testis (10:1). (B) Transcripts from individual genes have characteristic nucleotides or nucleotide
modifications at the first nucleotide position; Pabpc1 (poly(A) binding protein cytoplasamic 1), Apoa1 (apolipoprotein A-I), Prm2, (protamine 2), Alb
(albumin). (C) Schematic indicating the relative position of the nucleotide spots (left) and the location of the cold single stranded target sequences on the
hybridisation template (right). Single stranded DNA from the yeast gene IME2 was used as a negative control DNA in the hybridisations.
www.nature.com/scientificreports
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nucleotides upstream, whereas, Apoa1 strongly initiates at the A of
the Inr but also uses surrounding U, G, C and sites at a significant
level (Supplementary Figure S2 online) and (Fig. 4B).
Conversion of an adenosine following the m7G cap to Am (cap1)
can be followed by further conversion to m6Am (Fig. 1a, and 1c). It is
not known if this Am to m6Am conversion preferentially targets
certain messages, or if the Am:m6Am ratio for messages from
any one gene is merely a reflection of the general m6Am methylase
activity of a particular cell type. The enzyme responsible for the
formation of m6Am has been partially characterised5. It appears to
be a cytosolic enzyme and is distinct from METTL3/MT-A70, the
nuclear enzyme responsible for the formation of m6A at internal
positions within mRNA33.
Whilst there is evidence that cap1methylationmay increase trans-
lation efficiency18, 19, the consequences of converting a cap1 Am to
m6Amare largely unknown. Some crystallographic observations sug-
gest that the first nucleotide after the m7Gmay influence interaction
with eIF4E or other cap binding proteins. Crystallographic analysis
of eIF4E in a complex with the dinucleotidem7GpppG, show theG in
a disordered arrangement34. However, with m7GpppA as substrate,
the A interacts with a C-terminal loop of the protein35. A key inter-
action of this C-loop is a hydrogen bond between Thr205 and the
amino group in the N6 position of the adenosine. It is this amino
group that is targeted for methylation by them6Ammethylase. Thus,
N6 methylation of a cap1 adenosine might influence the flexibility
and orientation of the eIF4E C-terminal loop region. The ability to
synthesize RNA oligonucleotides that containe m6Am in well-
defined positions should facilitate future structure-function analysis.
Therefore a direct synthetic method for the preparation of the
desired m6Am phosphoramidite reagent, in a single step from com-
mercially available starting material via direct N6-methylation, dra-
matically improves access to thesematerials for biological evaluation.
Methods
Preparation of 2’-OMe-Bz-m6A-CE phosphoramidite. 59-(4,49-Dimethoxytrityl)-
6-N-benzoyl-6-N-methyl-adenosine,29-O-methyl-39-[(2-cyanoethyl)-(N,N-diiso-
propyl)]-phosphoramidite (2’-OMe-Bz-m6A-CE phosphoramidite) was prepared as
follows: tetrabutylammonium bromide (260 mg, 807 mmol) and aq. NaOH (1M,
7 ml) were added to a stirring solution of 2’-OMe-Bz-A-CE phosphoramidite (Link
Technologies, 708 mg, 797 mmol) and iodomethane (200 ml, 3.21 mmol) in
dichloromethane (7 ml). After vigorous stirring for 30 min, ether and water were
added and the resulting layers were separated. The aqueous layer was extracted with
ether, the combined organic extracts were dried over Na2SO4 and the volatiles
were removed in vacuo. 2’-OMe-Bz-m6A-CE phosphoramidite was readily
purified by column chromatography (1:1 petrol/etherR9:1 ether/methanol) afford-
ing 2’-OMe-Bz-m6A-CE phosphoramidite (403 mg, 56%, white foam, 1:1 mixture of
diastereoisomers) and 2’-OMe-Bz-m1A-CE phosphoramidite (182 mg, 25%, white
foam, 1:1 mixture of diastereoisomers). Data for 2’-OMe-Bz-m6A-CE phosphora-
midite and for 2’-OMe-Bz-m1A-CE phosphoramidite are presented in
Supplementary Table S1. online.
Synthesis of oligoribonucleotides SK-524 and SK-526. Oligoribonucleotides
SK-524(AmGGGCUGCU) and SK-526(m6AmGGGCUGCU) were synthesized on
an ABI 394 DNA/RNA synthesizer and mass spectra were recorded using a Bruker
Ultraflex III mass spectrometer via MALDI-TOF. Columns (SynBaseTM CPG
1000A˚, RNA: 0.2 mmol), apart from the 2’-OMe-Bz-m6A-CE phosphoramidite,
standard RNA-phosphoramidites and reagents for the synthesizer were purchased
from Link Technologies Ltd., MeNH2 solution (33 wt.% in ethanol) was obtained
from Fluka, NEt3N3HF, N-methylpyrrolidinone (NMP), 3-hydroxypicolinic acid
(HPA) and DowexTM 50WX8-200 were purchased from Aldrich, illustra NapTM-10
columns were obtained from GE Healthcare Europe GmbH. Dichloromethane and
acetonitrile were freshly distilled from CaH2 before use on the synthesizer.
The RNA oligonucleotides were synthesized using a standard 0.2 mM scale pro-
tocol, but with a 15 min coupling time for each nucleotide addition step. The poly-
mer-bound oligoribonucleotide was transferred from the synthesis column to a
1.5 ml microfuge tube and suspended in MeNH2 solution (1 ml). The mixture was
heated to 65 uC for 10 min, cooled to room temperature (water/icebath) and cen-
trifuged for 1 min (10,000 g). The supernatant was separated from the CPG beads,
the beads were washed with RNase free water (2 3 0.25 ml), all supernatants were
combined and dried (2 h under nitrogen stream, then freeze dried). The oligoribo-
nucleotide was resuspended in anhydrousNEt3N3HF/NEt3/NMP solution (250 ml of a
solution of 1.5 mlNMP, 750 mlNEt3 and 1.0 mlNEt3N3HF), heated to 65 uC for 1.5 h,
cooled to room temperature and quenched with 3M NaOAc solution (25 ml).
n-BuOH (1 ml) was added to the mixture, which was then thoroughly mixed, cooled
to270 uC for 1 – 2 h to encourage further precipitation and centrifuged for 30 min
(4 uC, 13 000 g). The supernatant was removed, the pellet washed with 70% EtOH
(23 500 ml) and then dried in vacuo (30 min). The dry precipitate was dissolved in
RNase free water (1 ml) and desalted using a NapTM-10 column following the
standard protocol. The resulting solution was freeze dried over night leaving the
oligoribonucleotide as a white foam/powder. Samples forMALDI-mass spectrometry
were prepared as follows36: DowexTM ion-exchange beads were rigorously cleaned
with dilute HCl, washed with water, then treated with dilute NH3 and finally washed
with water again to generate Dowex-NH41. Diammonium citrate (DAC) (100 mg)
was dissolved in water (1 ml) and HPA (34.8 mg) was dissolved in 1:1 acetonitrile/
water (1 ml). The HPA solution was filtered through Dowex-NH41 and the DAC
solution (100 ml) was added to prepare the matrix stock. Prior to MALDI-MS
acquisition, matrix stock (20 ml) was mixed with Dowex-NH41 (5 ml) and each
oligoribonucleotide sample (1 ml) was mixed with Dowex-NH41 (19 ml). After
30 min thematrix, and after drying, the sample solution (0.5ml) were spotted onto the
sample well and allowed to dry prior to confirmatory analysis by MALDI-MS.
RNA purification. Total RNA was prepared from mouse (C57BL/6) tissues using
Trizol reagent (Invitrogen). The poly(A) RNA was purified twice using oligo(dT)
cellulose (Fluka) followed by oligo(dT)magnetic beads (Invitrogen). All samples were
quantified and assayed for poly(A) purity using an Agilent Bioanalyser.
Analysis of gene-specific mRNA cap structures. Regions corresponding to the first
300 to 500 nucleotides of the target messages were PCR amplified from cDNAs using
the following oligonucleotides:
Apoa1forward GCTCCGGGGAGGTCACCCACACCT and
Apoa1reverse CAATGGGCCCAGCCGTTCCTGCAGC;
Albforward CCCCACTAGCCTCTGGCAAAATGAAGTG and
Albreverse GGCTGGGGTTGTCATCTTTGTGTTGCAG;
Prm2forward GCTGGGTGTGCGCGAGTCAGGGGCTC and
Prm2reverse CTTGTGGATCCTATGTAGCCTCTTACG;
Pabpc1forward CGGCGGTTAGTGCTGAGAGTGCGGAG and Pabpc1reverse
GAAGTTCACGTACGCGTAGCCCAAGG. Prior to amplification, the forward
oligonucleotides were 5’ phosphorylated, the amplification products were subse-
quently digested with lambda nuclease (New England BioLabs) to leave the single
stranded antisense DNA strand. 100 ng of this ssDNA (2 ml) was spotted onto
2 mm 3 2 mm teeth cut from a Hybond N1 membrane ( Amersham) (Fig. 2B,C),
and UV cross-linked (Stratalinker). Membranes were prehybridised at 42 uC in 40 %
formamide with 5 3 Denhardt’s, 3 % SDS, 0.3 M NaCl, 50 mM sodium phosphate
buffer (pH 7.0) and 0.1 mg ml21 sonicated salmon sperm DNA.
600 ng of poly(A) RNA was digested with 20 units of Tobacco Acid
Pyrophosphatase (Epicentre) for 30 minutes at 37 uC. The 5’ phosphate of the
exposed cap adjacent nucleotide was removed by the addition of 10 units of Alkaline
Phosphatase (Fermentas) and incubation for a further 15 minutes at 37 uC. After
phenol-chloroform extraction and ethanol precipitation, RNA samples were resus-
pended in 20 ml of sterile distilled water and 5’ ends were labelled using 30 units T4
polynucleotide kinase (PNK, Fermentas) and 7.4 MBq [c-32P] ATP at 37 uC for
30 minutes. The PNKwas heat inactivated (70 uC for 15 min) and the reaction made
up to 60 ml with sterile distilled water then passed through a P-30 spin column
(Bio-Rad) to remove unincorporated isotope. A 1 ml aliquot was taken, added to 9 ml
of nuclease P1 buffer and digested with P1 (Sigma) for one hour at 37 uC. 1.5 ml of the
released 5’ monophosphates from this digest was then analysed by 2D TLC as
described previously25. The remaining end labelled RNAwas fragmented to lengths of
approximately 120 nt by the addition of Na2CO3 to a final concentration of 60 mM
and NaHCO3 to a final concentration of 40 mM followed by incubation for one hour
at 60 uC.12 ml 3M sodium acetate pH 5.2 was then added and the RNA precipitated
with ethanol. The pellet was resuspended in 200 ml of pre-hybridisation buffer then
added to the membranes (final volume 2 ml) and hybridised overnight at 42 uC.
Membrane washings were carried out with 23, 13 and 0.23 SSC, 0.1% SDS. Two
final washes were carried out at 60 uC, with 0.2 3 SSC but with the SDS omitted.
Hybridised membranes were exposed to storage phosphor screens (K-screen;
KODAK) and imaged using Bio-Rad Molecular Imager FX in combination with
Quantity One 4.6.3 software (Bio-Rad). Individual teeth containing the target
mRNAs end labelled at the cap adjacent position were cut off and digested with P1
nuclease (Sigma) in a final volume of 3 ml. All of this digestion mix was applied to a
cellulose coated TLC plate (20 3 20 cm, MERCK) and developed as described
previously25.
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